Recovery Effect of Sugammadex Measured by Bispectral and Neurosense Indices

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

It has been demonstrated that antagonism of neuromuscular blockade (neostigmine 0.04 mg kg-1) affects depth of anaesthesia with an increase in bispectral index (mean maximal change of 7.1) and middle-latency auditory evoked potentials (mean maximal change of 9.7).

Sugammadex has a quicker and more complete effect than neostigmine. This study aims to demonstrate if sugammadex administration increases bispectral and neurosense indices of the depth of anesthesia while patients still receive propofol-remifentanil iv anesthesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hopital Foch

Criteria

Inclusion Criteria:

• patients scheduled to receive general anesthesia with muscle relaxation

Exclusion Criteria:

• contra-indication to the administration of propofol, remifentanil, rocuronium and to the use of the Bispectral Index or NeuroSense monitor

• known drug allergy or hypersensitivity to a drug used in the study

• history of central brain injury

• patient treated with a psychotropic agent

• patient with a pacemaker

• severe renal insufficiency

• treatment by toremifene, flucloxacillin or fusidic acid in the preoperative or immediate postoperative period